These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 8725851)
21. Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus. Sels JP; Kingma PJ; Wolffenbuttel BH; Menheere PP; Branolte JH; Nieuwenhuijzen Kruseman AC Neth J Med; 1994 Jun; 44(6):198-201. PubMed ID: 8052342 [TBL] [Abstract][Full Text] [Related]
22. Miglitol, a new alpha-glucosidase inhibitor. Sels JP; Huijberts MS; Wolffenbuttel BH Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557 [TBL] [Abstract][Full Text] [Related]
23. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Chiasson JL; Naditch L; Diabetes Care; 2001 Jun; 24(6):989-94. PubMed ID: 11375358 [TBL] [Abstract][Full Text] [Related]
24. Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients. Schnack C; Röggla G; Luger A; Schernthaner G Eur J Clin Pharmacol; 1986; 30(4):417-9. PubMed ID: 3527720 [TBL] [Abstract][Full Text] [Related]
25. Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. Standl E; Schernthaner G; Rybka J; Hanefeld M; Raptis SA; Naditch L Diabetes Res Clin Pract; 2001 Mar; 51(3):205-13. PubMed ID: 11269893 [TBL] [Abstract][Full Text] [Related]
26. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers. Sels JP; Nauta JJ; Menheere PP; Wolffenbuttel BH; Nieuwenhuijzen Kruseman AC Br J Clin Pharmacol; 1996 Oct; 42(4):503-6. PubMed ID: 8904624 [TBL] [Abstract][Full Text] [Related]
27. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673 [TBL] [Abstract][Full Text] [Related]
28. Effect of miglitol administration to non-insulin-dependent diabetic rats. Tormo MA; Ropero MF; Nieto M; Martinez IM; Campillo JE Gen Pharmacol; 1998 Jan; 30(1):125-9. PubMed ID: 9457493 [TBL] [Abstract][Full Text] [Related]
29. [The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office]. Fehmann HC Fortschr Med Orig; 2001 Jul; 119 Suppl 2():55-61. PubMed ID: 15704357 [TBL] [Abstract][Full Text] [Related]
30. HbA(1c) and glycemic profile, basal- and post-treatment with Miglitol, in an area with a Mediterranean diet. Faure E; Pallardo LF; Mesa J; Puig-Domingo M; García-Mayor R; Benito P; Ravella R; Artés M; López JS; Diabetes Care; 2002 Oct; 25(10):1896-8. PubMed ID: 12351510 [No Abstract] [Full Text] [Related]
31. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Scott LJ; Spencer CM Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834 [TBL] [Abstract][Full Text] [Related]
32. Effects of alpha-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus. Dimitriadis G; Hatziagellaki E; Alexopoulos E; Kordonouri O; Komesidou V; Ganotakis M; Raptis S Diabetes Care; 1991 May; 14(5):393-8. PubMed ID: 2060451 [TBL] [Abstract][Full Text] [Related]
33. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810 [TBL] [Abstract][Full Text] [Related]
34. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase. Joubert PH; Foukaridis GN; Bopape ML Eur J Clin Pharmacol; 1987; 31(6):723-4. PubMed ID: 3549325 [TBL] [Abstract][Full Text] [Related]
35. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms. Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the alpha-glucosidase inhibitor miglitol (BAY m 1099) in man. Lembcke B; Fölsch UR; Gatzemeier W; Ebert R; Siegel E; Creutzfeldt W Pharmacology; 1991; 43(6):318-28. PubMed ID: 1784628 [TBL] [Abstract][Full Text] [Related]
37. Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections. Kato H; Ohta A; Kobayashi S; Ishii S; Sada Y; Kobayashi H; Ohmori S; Kondo A; Katabami T; Fuse J; Fukuda H; Nagai Y; Tanaka Y Endocr J; 2012; 59(4):345-52. PubMed ID: 22301938 [TBL] [Abstract][Full Text] [Related]
38. Metabolic consequences of the alpha-glucosidase inhibitor BAY-M-1099 given to nondiabetic and diabetic rats fed a high-carbohydrate diet. Madar Z Am J Clin Nutr; 1989 Jan; 49(1):106-11. PubMed ID: 2643291 [TBL] [Abstract][Full Text] [Related]
39. Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099). Russell JC; Graham SE; Dolphin PJ Metabolism; 1999 Jun; 48(6):701-6. PubMed ID: 10381143 [TBL] [Abstract][Full Text] [Related]
40. The acute effects of glucosidase inhibition on post-meal glucose increments in insulin-dependent diabetics. Wing J; Kalk WJ; Berzin M; Diamond TH; Griffiths RF; Smit AM; Osler CE S Afr Med J; 1990 Mar; 77(6):286-8. PubMed ID: 2180090 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]